Bristol-Myers Squibb Co (XSWX:BMY) Debt-to-Equity : 3.48 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Bristol-Myers Squibb Co Debt-to-Equity?

Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF5,651 Mil. Bristol-Myers Squibb Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF45,363 Mil. Bristol-Myers Squibb Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was CHF14,653 Mil. Bristol-Myers Squibb Co's debt to equity for the quarter that ended in Mar. 2024 was 3.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bristol-Myers Squibb Co's Debt-to-Equity or its related term are showing as below:

XSWX:BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.4 Med: 0.8 Max: 3.48
Current: 3.48

During the past 13 years, the highest Debt-to-Equity Ratio of Bristol-Myers Squibb Co was 3.48. The lowest was 0.40. And the median was 0.80.

XSWX:BMY's Debt-to-Equity is ranked worse than
97.07% of 854 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XSWX:BMY: 3.48

Bristol-Myers Squibb Co Debt-to-Equity Historical Data

The historical data trend for Bristol-Myers Squibb Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Debt-to-Equity Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.92

1.37

1.27

1.31

1.41

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															1.24	1.23	1.35	1.41	3.48

Competitive Comparison of Bristol-Myers Squibb Co's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Debt-to-Equity falls into.

Bristol-Myers Squibb Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bristol-Myers Squibb Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2837.409	+	33020.658)	/	25451.064
	=	1.41

Bristol-Myers Squibb Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5650.607	+	45363.03)	/	14653.014
	=	3.48

Bristol-Myers Squibb Co (XSWX:BMY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bristol-Myers Squibb Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (XSWX:BMY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (XSWX:BMY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.